Abstract B089: Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neoepitopes as a prognostic biomarker

Author(s):  
Guilhem Richard ◽  
Randy F. Sweis ◽  
Leonard Moise ◽  
Matthew Ardito ◽  
William A. Martin ◽  
...  
2020 ◽  
Vol Volume 13 ◽  
pp. 12521-12538
Author(s):  
Liangliang Qing ◽  
Peng Gu ◽  
Mingsheng Liu ◽  
Jihong Shen ◽  
Xiaodong Liu ◽  
...  

2021 ◽  
Vol 9 ◽  
pp. 232470962110356
Author(s):  
Balraj Singh ◽  
Parminder Kaur ◽  
Sachin Gupta ◽  
Nirmal Guragai ◽  
Michael Maroules

Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.


BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yue Yang ◽  
Hanchao Zhang ◽  
Zhengdao Liu ◽  
Faliang Zhao ◽  
Guobiao Liang

AbstractBackgroundBladder cancer (BLCA) is a malignant urothelial carcinoma and has a high mortality rate. EPDR1 (ependymin related 1) is a type II transmembrane protein and related to calcium-dependent cell adhesion.MethodsWe explored the potential oncogenic roles of EPDR1 in BLCA basing on the multiple public datasets.ResultsWe found that EPDR1 expression had a significant difference in BLCA and adjacent normal bladder tissues, and the level of EPDR1was up-regulated with advanced tumor stage and metastasis in BLCA. Meanwhile, the high expression group of EPDR1 had a shorter OS compared to the low or medium expression-group. Furthermore, EPDR1 expression was associated with tumor-infiltrating immune cells (TIICs), including NK cells, CD8 + T cells, CD4 + T cells, Macrophages cells, and so on. Moreover, EPDR1 also involved in several signaling pathways as well as PI3K/AKT pathway, Cytokine receptor interaction, and apoptosis.ConclusionEPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in BLCA.


2013 ◽  
Vol 23 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Erik L. Brincks ◽  
Michael C. Risk ◽  
Thomas S. Griffith

Neoplasma ◽  
2019 ◽  
Vol 66 (02) ◽  
pp. 197-202 ◽  
Author(s):  
B. J. Chi ◽  
D. M. Zhao ◽  
L. Liu ◽  
X. Z. Yin ◽  
F. F. Wang ◽  
...  

2016 ◽  
Vol 27 (2) ◽  
pp. 294-299 ◽  
Author(s):  
N. Joseph ◽  
S.J. Dovedi ◽  
C. Thompson ◽  
J. Lyons ◽  
J. Kennedy ◽  
...  

1982 ◽  
Vol 128 (5) ◽  
pp. 931-935 ◽  
Author(s):  
Donald L. Lamm ◽  
Daniel E. Thor ◽  
Valerie D. Stogdill ◽  
Howard M. Radwin

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e56327 ◽  
Author(s):  
Cyrill A. Rentsch ◽  
Claire Biot ◽  
Joël R. Gsponer ◽  
Alexander Bachmann ◽  
Matthew L. Albert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document